Drugs / 19(T2)28z1xx CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04464200 | Jul 2020 → Jul 2026 overdue | B-cell chronic lymphocytic leukemia, Burkitt lymphoma, Waldenstrom macroglobulinemia, marginal zone lymphoma +2 | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 19(T2)28z1xx CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04464200 ↗ |
| Modality | Cell therapy | “1XX CAR T-cell products contain a higher proportion of CD8 T cells with memory features” PMID 39883889 ↗ Jan 2025 |
| Route | Intravenous | “patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.” NCT04464200 ↗ |
| Target | CD19 | “PURPOSE: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module” PMID 39883889 ↗ Jan 2025 |